Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PRAX
stocks logo

PRAX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
59.44K
-80.32%
-3.093
+5.21%
--
--
-3.306
+0.47%
--
--
-3.414
+3.16%
Estimates Revision
The market is revising Downward the revenue expectations for Praxis Precision Medicines, Inc. (PRAX) for FY2025, with the revenue forecasts being adjusted by -29.66% over the past three months. During the same period, the stock price has changed by 305.49%.
Revenue Estimates for FY2025
Revise Downward
down Image
-29.66%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-2.55%
In Past 3 Month
Stock Price
Go Up
up Image
+305.49%
In Past 3 Month
Wall Street analysts forecast PRAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRAX is 327.08 USD with a low forecast of 250.00 USD and a high forecast of 540.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast PRAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRAX is 327.08 USD with a low forecast of 250.00 USD and a high forecast of 540.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
0 Hold
0 Sell
Strong Buy
Current: 189.970
sliders
Low
250.00
Averages
327.08
High
540.00
Current: 189.970
sliders
Low
250.00
Averages
327.08
High
540.00
BTIG
NULL
to
Buy
initiated
$424
2025-11-18
Reason
BTIG
Price Target
$424
2025-11-18
initiated
NULL
to
Buy
Reason
BTIG initiated coverage of Praxis Precision with a Buy rating and $424 price target. The firm, which sees a greater than $5B greenfield opportunity for ulixacaltamide in essential tremor, also notes that Praxis also has a pair of sodium channel modulators, vormatrigine and relutrigine, with positive Phase 2 data in epilepsy and developmental and epileptic encephalopathy, respectively.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$232 -> $258
2025-11-13
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$232 -> $258
2025-11-13
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Praxis Precision to $258 from $232 and keeps a Buy rating on the shares after meeting with management. The firm believes Praxis is "poised for nether breakout" with the relutrigine readout nearing. Management offered details that should ease an investor concerns regarding the interim readout for EMBOLD Cohort 2 which should bring relutrigine to market in 2026, the analyst tells investors in a research note.
Chardan
Chardan
Buy
upgrade
$80 -> $330
2025-10-17
Reason
Chardan
Chardan
Price Target
$80 -> $330
2025-10-17
upgrade
Buy
Reason
Chardan raised the firm's price target on Praxis Precision to $330 from $80 and keeps a Buy rating on the shares. The company reported positive results from the Phase 3 studies of ulixacaltamide in essential tremor, which was an upside surprise given the very low expectations entering the event, the analyst tells investors in a research note. The firm believes the current data would be adequate to support a new drug application filing in early 2026 "despite some moving parts of the trials/data." Chardan models a "conservative" $2.5B in peak sales and 80% probability of success.
Deutsche Bank
NULL -> Buy
upgrade
$65 -> $280
2025-10-17
Reason
Deutsche Bank
Price Target
$65 -> $280
2025-10-17
upgrade
NULL -> Buy
Reason
Deutsche Bank raised the firm's price target on Praxis Precision to $280 from $65 and keeps a Buy rating on the shares. The company reported a "surprise win" for ulixacaltamide in essential tremor, the analyst tells investors in a research note. The firm remains a buyer of the stock after yesterday's big rally on its potential in epilepsy.
Guggenheim
Buy
upgrade
$155 -> $350
2025-10-16
Reason
Guggenheim
Price Target
$155 -> $350
2025-10-16
upgrade
Buy
Reason
Guggenheim raised the firm's price target on Praxis Precision to $350 from $155 and keeps a Buy rating on the shares following two positive pivotal trial readouts for ulixacaltamide in essential tremor. Given the unmet need and "robustness" of the data, the firm estimates the ET opportunity to be worth over $2B in the U.S. and it assumes 80% odds of potential approval.
Jefferies
Andrew Tsai
Buy
upgrade
$65 -> $300
2025-10-16
Reason
Jefferies
Andrew Tsai
Price Target
$65 -> $300
2025-10-16
upgrade
Buy
Reason
Jefferies analyst Andrew Tsai raised the firm's price target on Praxis Precision to $300 from $65 and keeps a Buy rating on the shares. The firm expects "significant stock upside" following ulixacaltamide's Phase 3 Essential3 program success in essential tremor, which it sees as a $2.5B-plus opportunity. The firm, which sees the data enabling Praxis to submit an NDA in early 2026, sees 70% odds of success for approval.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Praxis Precision Medicines Inc (PRAX.O) is -14.16, compared to its 5-year average forward P/E of -4.61. For a more detailed relative valuation and DCF analysis to assess Praxis Precision Medicines Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.61
Current PE
-14.16
Overvalued PE
-0.38
Undervalued PE
-8.85

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.01
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.92
Undervalued EV/EBITDA
-6.93

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
562.68
Current PS
0.00
Overvalued PS
1717.01
Undervalued PS
-591.66
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 587.88% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 587.88% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PRAX News & Events

Events Timeline

(ET)
2025-12-04
19:40:00
U.S. Equity Futures Little Changed, Tech Stocks Mixed Performance
select
2025-12-04
17:10:00
Praxis Precision Submits EMBOLD Study Results, FDA to Review Data
select
2025-12-04
16:10:00
Praxis Precision Completes Pre-NDA Meeting with FDA
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11:00 AMNASDAQ.COM
Healthcare and Biotech Stocks Surge in After-Hours Trading: Sensei, Praxis, Cooper, Vanda, Cue, ResMed

  • Sensei Biotherapeutics Surge: Sensei Biotherapeutics Inc. saw a significant after-hours increase of 62.9% to $17.20, following a previous rise and a report of a narrower third-quarter net loss compared to the previous year.

  • Praxis Precision Medicines Progress: Praxis Precision Medicines, Inc. rose 24.8% to $237.10 after positive EMBOLD study results led to an early recommendation for stopping the study, with plans for an NDA filing in early 2026.

  • CooperCompanies Financial Update: The CooperCompanies, Inc. climbed 13.0% to $87.01 after reporting a fourth-quarter net income decline but positive revenue growth, alongside a strategic review to enhance shareholder value.

  • Vanda Pharmaceuticals FDA Approval: Vanda Pharmaceuticals Inc. gained 7.5% to $5.59 after the FDA lifted a partial clinical hold on a protocol, allowing for expanded dosing of tradipitant following a successful dispute resolution request.

[object Object]
Preview
9.0
05:20 AMGlobenewswire
Praxis Stops EMBOLD Study Early Due to Positive Efficacy Results
  • Significant Study Results: Praxis Precision Medicines announced positive outcomes from the EMBOLD study, leading to an early stop recommendation by the Data Monitoring Committee, marking a crucial advancement in treating SCN2A and SCN8A developmental epileptic encephalopathies.
  • FDA Meeting Confirmation: The company has confirmed a meeting with the FDA to discuss the data and NDA pathway for relutrigine, which is expected to accelerate the drug's market entry to meet urgent therapeutic needs.
  • Clinical Trial Success: In the Phase 2 EMBOLD study, relutrigine demonstrated a favorable safety profile and significant short- and long-term improvements in seizure control, potentially offering the first effective treatment option for patients with severe epilepsy.
  • Huge Market Potential: Relutrigine has received Orphan Drug and Breakthrough Therapy Designations, indicating its significant market value in treating SCN2A and SCN8A epilepsies, which is anticipated to generate substantial economic returns for the company.
[object Object]
Preview
4.0
12-01Benzinga
Needham Affirms Buy Rating on Praxis Precision Medicine, Keeps $250 Price Target

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing trading strategies.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.

  • Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Praxis Precision Medicines Inc (PRAX) stock price today?

The current price of PRAX is 189.97 USD — it has increased 2.05 % in the last trading day.

arrow icon

What is Praxis Precision Medicines Inc (PRAX)'s business?

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.

arrow icon

What is the price predicton of PRAX Stock?

Wall Street analysts forecast PRAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRAX is 327.08 USD with a low forecast of 250.00 USD and a high forecast of 540.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Praxis Precision Medicines Inc (PRAX)'s revenue for the last quarter?

Praxis Precision Medicines Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Praxis Precision Medicines Inc (PRAX)'s earnings per share (EPS) for the last quarter?

Praxis Precision Medicines Inc. EPS for the last quarter amounts to -3.36 USD, increased 22.18 % YoY.

arrow icon

What changes have occurred in the market's expectations for Praxis Precision Medicines Inc (PRAX)'s fundamentals?

The market is revising Downward the revenue expectations for Praxis Precision Medicines, Inc. (PRAX) for FY2025, with the revenue forecasts being adjusted by -29.66% over the past three months. During the same period, the stock price has changed by 305.49%.
arrow icon

How many employees does Praxis Precision Medicines Inc (PRAX). have?

Praxis Precision Medicines Inc (PRAX) has 116 emplpoyees as of December 05 2025.

arrow icon

What is Praxis Precision Medicines Inc (PRAX) market cap?

Today PRAX has the market capitalization of 4.75B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free